Multifunctional nanoparticle platform for targeted delivery and vaccines.

Anja S Redecker, Medea Neek, Philip E J Smith, James R Swartz

Abstract read

In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Microbial cell-free protein synthesis and its progression toward industrial use.Microbiology (Reading, England) · 2026
Review
Noncanonical amino acids enable plug and play vaccine platform in the ALiCE cell free system.NPJ vaccines · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anja S RedeckerDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.

Medea NeekDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.

Philip E J SmithDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.

James R SwartzDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a versatile, targeted delivery platform based on the Hepatitis B core protein virus-like particle (VLP). Multiple protein mutations were combined with cell-free protein synthesis and anaerobic processing to enable reliable production of nanoparticles (NPs) loaded with single or multiple cargoes (typically with concentration factors >10ˆ4) and functionalized with single or multiple surface adducts. Our design supports multiple functional requirements while also enabling flexible and reliable production. Process yields are about 6 x 10

Indexed as

BiochemistryBiomaterialsDrug delivery systemNanoparticlesTherapeutics

Identifiers

PMID40496813

DOI10.1016/j.isci.2025.112599

PMCPMC12150064

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.